A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Limited-Stage Small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Limited-Stage Small Cell Lung Cancer focused on measuring Limited-Stage Small Cell Lung Cancer, Serplulimab
Eligibility Criteria
Inclusion Criteria:
- Male or female, aged ≥18 years when signing the ICF.
- Histologically diagnosed with SCLC.
- Diagnosed with LS-SCLC (stage Ⅰ-Ⅲ of the AJCC 8th edition of the cancer staging), which can be safely treated with curative radiation doses.
- Major organs are functioning well.
Exclusion Criteria:
- Histologically or cytologically confirmed mixed SCLC.
- Subjects suitable for surgery. Subjects who are suitable for surgery but refuse surgical treatment can be included.
- Patients who have previously received systematic anti-tumor treatments for small cell lung cancer, including but not limited to radiotherapy, chemotherapy, and immunotherapy.
- Patients with other active malignancies within 5 years or at the same time.
- Subjects with known history of severe allergy to any monoclonal antibody.
- Subjects with known anaphylaxis to carboplatin/cisplatin or etoposide.
- In the judgment of the investigator, subjects who have any other factors that may lead to a premature discontinuation.
Sites / Locations
- OPN-GlendaleRecruiting
- OPN-Los AlamitosRecruiting
- Southern California Permanente GroupRecruiting
- Emad Ibrahim, MD, IncRecruiting
- Providence Medical FoundationRecruiting
- Lutheran Medical Center - Cancer Centers of Colorado
- Eastern Connecticut Hematology & Oncology AssociatesRecruiting
- Cancer Specialists of North FloridaRecruiting
- Mid Florida Hematology and Oncology CenterRecruiting
- Advent Health OrlandoRecruiting
- Napa Research
- Kansas University Mediacal Center
- Pontchartrain Cancer CenterRecruiting
- Tulane UniversityRecruiting
- Health PartnersRecruiting
- Renown HealthRecruiting
- Dartmouth Hitchcock Medical CenterRecruiting
- Montefiore Medical CenterRecruiting
- New York City Health+HospitalsCorporation Elmhurst Hospital Center
- Northwell Health
- Cleveland Clinic Mercy HospitalRecruiting
- Gabrail Cancer Center
- Tricounty Hematology and Oncology AssociatesRecruiting
- Kaiser Permanente NorthwestRecruiting
- The Center for Cancer and Blood DisordersRecruiting
- Millennium Research & Clinical DevelopmentRecruiting
- Pro Research Tools, INC DBA Lumi ResearchRecruiting
- The University of Texas - Hope Cancer CenterRecruiting
- Innova Schar Cancer Insitute
- Northwest Medical SpecialtiesRecruiting
- Klinikum Klagenfurt am Worthersee
- Klinikum Klagenfurt am Wörthersee
- Karl Landsteiner Institut für Lungenforschung und pneumologische Onkologie, c/o Klinik Floridsdorf Abteilung für Innere Medizin und Pneumologie
- Karl Landsteiner Institute for Lung Research and Pneumological Oncology, c/o Klinik Floridsdorf Department for Inner Medicine und Pneumology
- The First Affiliated Hospital of Bengbu Medical College
- Anhui Chest Hospital
- Cancer Hospital Chinese Academy of Medical Sciences
- Beijing Cancer Hospital
- The First Affiliated Hospital of Chongqing Medical
- Chongqing University Cancer Hospital
- Fujian Cancer Hospital
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- Sun Yat-Sen University Cancer Center
- Peking University Shenzhen Hospital
- The Second Affiliated Hospital of Guilin Medical University
- Guangxi Medical University Cancer Hospital
- Gungzhouyikedaxuefushuzhongliuyiyuan
- Affiliated Hospital of Hebei University
- Cangzhou People's Hospital
- Tangshan People's Hospital
- Harbin Medical University Cancer Hospital
- Jiamusi Cancer Hospital
- The First Affiliated Hospital of Henan University of Science and Technology
- The First Affiliated Hospital of Xinxiang Medical University
- Henan Cancer Hospital
- The First Affiliated Hospital of Zhengzhou University
- Hong Kong United Oncology CentreRecruiting
- Queen Elizabeth HospitalRecruiting
- Queen Mary HospitalRecruiting
- TaiHe Hospital Affiliated Hospital of Hubei University of Medicine
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
- Zhongnan hospital of wuhan university
- Hubei Cancer Hospital
- The First People's Hospital Of Changde City
- The Second Xiangya Hospita
- Hunan Cancer Hospital
- Xiangya Hospital Central South University
- Xuzhou Central Hospital
- Northern Jiangsu people's Hospital
- First Affiliated Hospital of Gannan Medical University
- Ganzhou Cancer Hospital
- The First Affiliated Hospital of Nanchang University
- Jilin Cancer Hospital
- Liaoning Cancer Hospital & Institute
- Shenyang The Tenth People's Hospital
- Qilu Hospital of Shandong University
- Shandong Cancer Hospital
- Linyi Tumor Hospital
- Affiliated Hospital of Qingdao University
- Shanghai Chest Hospital
- Fudan University Shanghai Cancer Center
- Zhongshan Hospital of Fudan University
- Wenzhou University Hospital
- Baoji Central Hospital
- Shanxi Provincial Cancer Hospital
- First Affiliated Hospital of Xi'an Jiaotong University
- West China Hospital of Sichuan University
- Tianjin Medical University Cancer Institute & Hospital
- Tianjin Medical University General Hospital
- The Second People's Hospital Of Yibin
- Yunnan Cancer Hospital
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
- Yuhang Branch of the First Affiliated Hospital of Zhejiang University
- Zhejiang Cancer Hospital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Taizhou Hospital of Zhejiang Province
- The 1st Affiliated Hospital of WMU
- University Hospital Brno (Clinic For Lung Diseases and Tuberculosis)
- University Hospital Brno
- University Hospital Olomouc (Oncology Clinic)
- University Hospital Ostrava (oncology department)
- University Hospital Ostrava
- Nemocnice AGEL Ostrava-Vítkovice
- Nemocnice AGEL Ostrava-Vítkovice
- University Hospital Motol
- University Hospital Motol (Pneumology Clinic 2.LF UK and FN Motol)
- General University hospital in Prague (Oncology department)
- Kliniken der Stadt Cologne GmbH
- University hospital Schleswig-Holstein
- "Sotiria" Thoracic Diseases General Hospital of Athens
- General Hospital of Athens "Alexandra"
- Fejer County Szent Gyorgy University Teaching Hospital
- Pulmonary Institute of Torokbalint
- Riga East University Hospital, Latvian Oncology Center
- Clinic of Oncology, Pauls Stradins Clinical university hospital
- Hospital St. Jansdal
- Isala Hospital
- MedPoloniaSp. z o.o.
- Lung and Chest Cancer Clinic, National Institute of Oncology
- Hospital German Trias i Pujol/ ICO Badalona
- University Hospital La Fe
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Serplulimab + carboplatin/cisplatin-etoposide + radiotherapy
placebo + carboplatin/cisplatin-etoposide + radiotherapy
Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus Serplulimab 300 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.
Participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus placebo every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, with maximum 1 year after completion of cCRT or until disease progression, intolerable toxicity or other reasons specified in the protocol, whichever occurs first.